HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
Greg.Corboy1 (talk | contribs) Update GC authors 5th addition and remove pendings |
Greg.Corboy1 (talk | contribs) Update GC authors for 5th addition and remove pendings |
||
| Line 1,068: | Line 1,068: | ||
|Disease | |Disease | ||
|Daynna Wolff | |Daynna Wolff | ||
| | |5/3/2025 | ||
| | |8/3/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,110: | Line 1,110: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 1,126: | Line 1,126: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 1,148: | Line 1,148: | ||
|Disease | |Disease | ||
|Muhammad Zulfiqar, MD | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,165: | Line 1,165: | ||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,181: | Line 1,181: | ||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,197: | Line 1,197: | ||
|Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | |Mayuri Shende (trainee) and Scott Turner (mentor)<br /> | ||
|9/22/24 | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,227: | Line 1,227: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,239: | Line 1,239: | ||
|Complete | |Complete | ||
|10/01/2021 | |10/01/2021 | ||
|Date completed by author: 10/01/2021 | |Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | ||
|- | |- | ||
!Disease (5th Edition) | !Disease (5th Edition) | ||
| Line 1,291: | Line 1,291: | ||
|Disease | |Disease | ||
|Muhammad Zulfiqar, MD | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,307: | Line 1,307: | ||
|Disease | |Disease | ||
|Muhammad Zulfiqar, MD | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,354: | Line 1,354: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,365: | Line 1,365: | ||
|Sudha Arumugam, MD | |Sudha Arumugam, MD | ||
|Complete | |Complete | ||
|01/24/2022 | |01/24/2022. Emailed 5/1/2025, no response | ||
|Date completed by author: 01/24/2022 | |Date completed by author: 01/24/2022 | ||
|- | |- | ||
| Line 1,962: | Line 1,962: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
| Line 1,977: | Line 1,977: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| || || || ||GC|| || | |5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| || | ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| Line 1,985: | Line 1,985: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
| | | | ||
| | | | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
|Complete | |Complete | ||
|5/26/2021 | |5/26/2021. Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| | |Complete | ||
|27/01/2022 | |27/01/2022 Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
| Line 2,047: | Line 2,047: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | ||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
| Line 2,062: | Line 2,062: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
| Line 2,070: | Line 2,070: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| | | |6/28/2025 | ||
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| Line 2,085: | Line 2,086: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| | | |5/6/2025 | ||
|8/6/2025 Emailed 9/4/2025 to remind | |||
| || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
| Line 2,107: | Line 2,110: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
|Complete | |Complete | ||
|16/11/2021 | |16/11/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
|Complete | |Complete | ||
|28/06/2021 | |28/06/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
| Line 2,197: | Line 2,200: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease|| | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu | ||
| | | |5/7/2025 | ||
|8/7/2025 Reminder email sent 9/4/2025|| || | |||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
| Line 2,207: | Line 2,211: | ||
|- | |- | ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | ||
| | | |7/4/2025 | ||
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,874: | Line 2,879: | ||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||